Page 83 - Read Online

Song et al. Hepatoma Res 2020;6:27 I http://dx.doi.org/10.20517/2394-5079.2020.05 Page 11 of 15

entecavir in patients with chronic HBV infection in China. Gastroenterology 2020;158:215-25.e6.
5. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat
Rev Gastroenterol Hepatol 2019;16:411-28.
6. Kanwal F, Kramer J, Li L, Dai J, Natarajan Y, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in non-
alcoholic fatty liver disease. Hepatology 2020;71:808-19.
7. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors
and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.
8. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al. Nonalcoholic steatohepatitis is the fastest growing cause of
hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.
9. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. Modeling NAFLD disease burden in China, France, Germany,
Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
10. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
11. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving
outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8.
12. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol 2019;16:617-30.
13. Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology
2019;70:1437-42.
14. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, et al. Integration of tumour and viral genomic characterizations in HBV-related
hepatocellular carcinomas. Gut 2015;64:820-9.
15. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996;348:625-6.
16. Iavarone M, Trabut JB, Delpuech O, Carnot F, Colombo M, et al. Characterisation of hepatitis B virus X protein mutants in tumour
and non-tumour liver cells using laser capture microdissection. J Hepatol 2003;39:253-61.
17. Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A, Zakaria MK, et al. Hepatitis B virus, HBx mutants and their role in hepatocellular
carcinoma. World J Gastroenterol 2014;20:10238-48.
18. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature
1991;351:317-20.
19. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol
Hepatol 2011;26:144-52.
20. Jiang T, Liu M, Wu J, Shi Y. Structural and biochemical analysis of Bcl-2 interaction with the hepatitis B virus protein HBx. Proc Natl
Acad Sci U S A 2016;113:2074-9.
21. Niu Y, Xu M, Slagle BL, Huang H, Li S, et al. Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced
hepatocarcinogenesis. Hepatology 2017;65:893-906.
22. Jegal ME, Jung SY, Han YS, Kim YJ. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7
hepatocellular carcinoma cells. BMB Rep 2019;52:330-5.
23. Li Y, Fu Y, Hu X, Sun L, Tang D, et al. The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular
carcinoma via CREB1. Cell Death Dis 2019;10:405.
24. Lee S, Kim W, Ko C, Ryu WS. Hepatitis B virus X protein enhances Myc stability by inhibiting SCF(Skp2) ubiquitin E3 ligase-
mediated Myc ubiquitination and contributes to oncogenesis. Oncogene 2016;35:1857-67.
25. Wang J, Li N, Huang ZB, Fu S, Yu SM, et al. HBx regulates transcription factor PAX8 stabilization to promote the progression of
hepatocellular carcinoma. Oncogene 2019;38:6696-710.
26. He B, Peng F, Li W, Jiang Y. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in
HepG2 through PI3K/Akt signaling. J Cell Biochem 2019;120:2908-18.
27. Lin X, Zuo S, Luo R, Li Y, Yu G, et al. HBX-induced miR-5188 impairs FOXO1 to stimulate beta-catenin nuclear translocation and
promotes tumor stemness in hepatocellular carcinoma. Theranostics 2019;9:7583-98.
28. Chen SL, Zhang CZ, Liu LL, Lu SX, Pan YH, et al. A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related
hepatocellular carcinoma. Cancer Res 2019;79:534-45.
29. Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, et al. Hepatocellular carcinoma-associated single-nucleotide variants and deletions
identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J Pathol 2017;243:176-92.
30. Bai X, Jia JA, Fang M, Chen S, Liang X, et al. Deep sequencing of HBV pre-S region reveals high heterogeneity of HBV genotypes
and associations of word pattern frequencies with HCC. PLoS Genet 2018;14:e1007206.
31. Huang JT, Liu YJ, Wang J, Xu ZG, Yang Y, et al. Next generation digital PCR measurement of hepatitis B virus copy number in
formalin-fixed paraffin-embedded hepatocellular carcinoma tissue. Clin Chem 2015;61:290-6.
32. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce
oxidative stress and DNA damage. Carcinogenesis 2004;25:2023-32.
33. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J
Hepatol 2014;61:408-17.
34. Li TN, Wu YJ, Tsai HW, Sun CP, Wu YH, et al. Intrahepatic hepatitis B virus large surface antigen induces hepatocyte hyperploidy via
failure of cytokinesis. J Pathol 2018;245:502-13.
35. Liu P, Zhang H, Liang X, Ma H, Luan F, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the
tumorigenesis of hepatocellular carcinoma. Oncotarget 2015;6:29048-59.
36. Luan F, Liu B, Zhang J, Cheng S, Zhang B, et al. Correlation between HBV protein preS2 and tumor markers of hepatocellular
carcinoma. Pathol Res Pract 2017;213:1037-42.